Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial (Q33750154)

29 July 2017

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial (English)

1 reference

29 July 2017

phase III clinical trial

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Robert Motzer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

B Escudier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

T E Hutson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

J I Clark

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

H Y Lim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

E Porfiri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

P Zalewski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

G Kannourakis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Staehler

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

J Tarazi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

B Rosbrook

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

L Cisar

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

S Hariharan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

S Kim

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

B I Rini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

13 May 2014

1 reference

British Journal of Cancer

29 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

2821-2828

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

3 June 2020

copyright license

start time

13 May 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bjc.2014.244

0 references

cites work

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Sorafenib in advanced clear-cell renal-cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.

14 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.244

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.244

Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.244

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.244

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056058

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24823696

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2014.244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24823696%20AND%20SRC:MED&resulttype=core&format=json